LOGIN  |  REGISTER
Astria Therapeutics

Palatin Technologies to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

February 10, 2023 | Last Trade: US$0.97 0.11 12.56

CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

  

Q2 Fiscal Year 2023 Results Press Release 

02/15/2023 at 7:30 a.m. ET

  

Q2 Fiscal Year 2023 Conference Call-Live

02/15/2023 at 11:00 a.m. ET

     US Toll Free Dial-In Number:

1-888-506-0062

     International Dial-In Number:

1-973-528-0011

     Participant Access Code:

928705

  

Q2 Fiscal Year 2023 Conference Call-Replay

02/15/2023-03/01/2023

     US Toll Free Dial-In Number:

1-877-481-4010

     International Dial-In Number:

1-919-882-2331

     Participant Access Code:

47637

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by accessing this link.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB